Medication approval journey
escitalopram (Lexapro)
Approved for Major depressive disorder in adults
page first published · last updated
Also answers to “the remastered single” — its codename in our videos and posts. The full codebook
How this page reads
The page as written, with the clinical terms
Plain language uses the same facts, the same numbers and the same caveats. It does not leave anything out. Quotes from the FDA label are never reworded in either setting.
Before you stop or change your escitalopram dose
Stopping abruptly causes withdrawal effects that can be severe
Stopping or reducing an SSRI too fast commonly causes withdrawal symptoms — dizziness, electric-shock sensations, insomnia, agitation. These are often more severe and far longer-lasting than the "one to two weeks" many people are told. Any change should be a slow, prescriber-supervised taper.
what the escitalopram warnings mean
label facts below are read from the escitalopram FDA label on DailyMed, set id 9ddd1f24-3ebd-4307-bb23-6acd742cd140, version 1, effective july 24, 2026. the section numbers in brackets are the label’s own. every source is linked at the end of this section. last checked 2026-10-05.
escitalopram was approved for depression in 2002, and about 9.5 million americans filled a prescription for it in 2024 [meps]. it is the active half of citalopram, which is why its label and citalopram’s share so much. the label carries one boxed warning and ten further warnings. this section says what each means in plain words, what the approval trials measured and for how long, which side effects the label counts and how often at each dose, and what independent research has found since, in both directions. every number is from the label or from a study in the library, and each source is linked at the end.
this is information to take to a prescriber. nothing here is a reason to start, stop or change a dose on your own; the label itself says stopping suddenly is the thing to avoid.
the boxed warning: suicidal thoughts and behaviors, by age
the boxed warning says antidepressants increased the risk of suicidal thoughts and behaviors in children, adolescents and young adults in short-term studies, that everyone on the drug should be watched for worsening, and that escitalopram is not approved under age 7 [label, boxed warning and 5.1].
the numbers come from pooled placebo-controlled trials of antidepressants covering about 77,000 adults and 4,500 children. the label gives the difference against placebo per 1,000 people treated: under 18, 14 additional people with suicidal thoughts or behaviors; 18 to 24, 5 additional; 25 to 64, 1 fewer; 65 and older, 6 fewer [label 5.1, table 1]. the label adds that the absolute risk was highest in people treated for depression, and that whether the risk extends beyond four months is unknown.
so the warning is specific. it is about thoughts and behaviors, not deaths; it is about the first months; and above age 24 the pooled trials showed no increase [label 5.1; age-ceiling row]. for someone under 25 the question is who is watching and for what. for someone over 65 the number runs the other way.
the ten other warnings, in plain words
the label’s warnings and precautions run from 5.2 to 5.11. none is boxed. each is a mechanism the fda considers real enough to print; how often it hurts anyone is a separate question, and where a study has measured that, it is in the research section below.
- serotonin syndrome [5.2]: too much serotonin signalling, which can be life-threatening. the risk rises with other serotonergic drugs (the label names triptans, tricyclics, fentanyl, meperidine, methadone, lithium, tramadol, buspirone, amphetamines and st john’s wort) and the combination with an maoi is contraindicated. it can happen on escitalopram alone. signs are agitation or confusion, racing heart, sweating, fever, tremor, muscle jerking and overactive reflexes.
- discontinuation syndrome [5.3]: stopping, particularly abruptly, can bring low mood, irritability, agitation, dizziness, electric-shock sensations, anxiety, confusion, headache, insomnia and hypomania. the label says these are generally self-limiting but serious cases have been reported, recommends gradual reduction, and says that if a reduction brings intolerable symptoms the prescriber may consider returning to the previous dose and tapering more slowly.
- seizures [5.4]: people with a seizure disorder were excluded from the trials; convulsions were still reported in trials, so the label says to introduce the drug with care in anyone with a seizure history.
- activation of mania or hypomania [5.5]: in someone with bipolar disorder an antidepressant can tip a depressive episode into a manic one. in the depression trials it happened in 1 of 715 people on escitalopram (0.1%) and none of 592 on placebo. the label tells prescribers to screen for a personal or family history first.
- low sodium [5.6]: hyponatremia, usually from the hormone syndrome siadh and reversible on stopping, with cases below 110 mmol/l reported. early signs are headache, poor concentration, confusion, weakness and unsteadiness; severe cases have included seizures and death. older people, people on diuretics and anyone dehydrated may be at greater risk.
- bleeding [5.7]: drugs that block serotonin reuptake make platelets less effective. aspirin, nsaids such as ibuprofen and naproxen, and blood thinners add to the risk, and ssri use in the month before delivery has been linked to a less than twofold rise in postpartum bleeding.
- thinking and driving [5.8]: in a study of healthy volunteers, 10 mg a day did not impair intellectual function or psychomotor performance. the label still says to be careful with machinery and cars until you know how the drug affects you.
- angle-closure glaucoma [5.9]: the pupil dilation many antidepressants cause can trigger an attack in an eye with narrow drainage angles that has not been treated.
- other illnesses [5.10]: the drug was not systematically studied in people with a recent heart attack or unstable heart disease, who were excluded from the trials. in liver impairment the recommended dose is 10 mg a day because the drug is cleared more slowly.
- sexual dysfunction [5.11]: delayed or absent ejaculation, erectile dysfunction and reduced desire in men; reduced desire and delayed or absent orgasm in women. the label tells prescribers to ask before starting and to ask again during treatment, because people do not volunteer it.
what the trials measured, and for how long
the depression approval rested on three placebo-controlled trials in adult outpatients aged 18 to 65, each lasting 8 weeks, with change on the montgomery-asberg depression rating scale as the outcome. one fixed-dose trial compared 10 mg and 20 mg a day with placebo and with citalopram 40 mg, and found 10 mg and 20 mg similar; a second compared 10 mg with placebo; a third let the dose move between 10 and 20 mg against placebo and citalopram [label 14.1]. the label gives no enrollment per trial; 715 people took escitalopram across the placebo-controlled depression trials [label 6.1].
a longer trial took 274 people who had responded to 8 weeks of open-label escitalopram and randomised them to continue or switch to placebo for up to 36 weeks. time to relapse was longer on escitalopram [label 14.1]. the label states the result as a time difference and gives no relapse percentages. that design cannot separate relapse from withdrawal effects, because the placebo group had just stopped the drug.
the arithmetic that matters: the efficacy trials were 8 weeks, the longest controlled measurement behind the approval was 36 weeks, the trials excluded people with seizure disorders, recent heart disease and anyone under 18 or over 65, and about 9.5 million americans a year now take it. how long people stay on it is on the longest-trial page linked below.
the most common side effects, with the label’s numbers
the label pools 715 people on escitalopram against 592 on placebo in the depression trials and reports the reactions at about 5% or more and twice placebo: nausea 15% vs 7%, insomnia 9% vs 4%, diarrhea 8% vs 5%, sleepiness 6% vs 2%, dry mouth 6% vs 5%, increased sweating 5% vs 2%, fatigue 5% vs 2%, dizziness 5% vs 3% [label 6.1]. the full list is in the side-effects section lower on this page.
the label also splits several of these by dose, and the gap between 10 mg and 20 mg is large: insomnia 7% at 10 mg and 14% at 20 mg (placebo 4%), diarrhea 6% and 14% (placebo 5%), dry mouth 4% and 9% (placebo 3%), sleepiness 4% and 9% (placebo 1%), increased sweating 3% and 8% (placebo under 1%), fatigue 2% and 6% (placebo 2%) [label 6.1, table 4]. since the efficacy trials found 10 mg and 20 mg similar on the depression scale, the dose is a question worth asking.
sexual side effects have their own table. in men (407 on escitalopram, 383 on placebo): ejaculation disorder, mostly delay, 12% vs 1%; decreased libido 6% vs 2%; impotence 2% vs under 1%. in women (737 vs 636): decreased libido 3% vs 1%; anorgasmia 3% vs under 1% [label 6.1, table 5]. the label says in its own words that these estimates "are likely to underestimate their actual incidence" and that there are no adequately designed studies of sexual dysfunction with escitalopram.
two cautions the label attaches to all of these: rates from trials cannot be compared directly with rates for other drugs, and they may not match what happens in ordinary practice.
what independent research says, in both directions
in favour. the largest comparison of antidepressants ever done, 522 randomised trials with 116,477 adults, found escitalopram one of the few drugs that was both more effective and better tolerated than most others in head-to-head trials [cipriani-2018]. the same group’s earlier analysis of 117 trials and 25,928 adults put it among the four most effective of 12 newer antidepressants and, with sertraline, the least often stopped [cipriani-2009]. the cochrane review pooling 22 trials and about 4,000 people found it modestly more effective than citalopram and fluoxetine, with fewer people stopping it than stopping duloxetine [cochrane-2009]. when sexual function was measured with a questionnaire across antidepressants, escitalopram sat near the bottom of the ranking, below sertraline, venlafaxine, citalopram and paroxetine [serretti-2009].
against, or smaller than the badge suggests. an analysis of individual data from 73,388 people in 232 placebo-controlled trials submitted to the fda, escitalopram’s among them, found antidepressants beat placebo by an average of 1.75 points on a 52-point depression scale, with roughly 15% of people getting a substantial benefit beyond the placebo response [stone-2022]. in 177 adults aged 60 and over with generalised anxiety, 69% responded within 12 weeks against 51% on placebo among those who finished the trial, but counting everyone who started the difference was 57% against 45% and not statistically significant; fatigue and sleepiness affected about 41% [lenze-2009]. in 66 healthy volunteers, three weeks of 20 mg reduced how much choices shifted in response to reward and punishment, which the authors said may reflect the emotional blunting patients report; memory, inhibition and flexibility were unchanged, and the authors wrote "may reflect", not "is" [langley-2023]. in may 2019 the european regulator’s safety committee ordered every maker of escitalopram and nine related drugs to add a warning that sexual dysfunction can continue after the drug is stopped; how often is unknown, and that uncertainty cuts both ways [prac-2019].
where the warnings have been measured. the bleeding warning is real but modest: across 15 case-control and 4 cohort studies the odds of an upper-gi bleed on an ssri were 1.66 times, which is one extra bleed for roughly every 3,177 low-risk people or 881 high-risk people; with an nsaid as well the odds rose to 4.25 times [anglin-2014]. on withdrawal, the uk guideline nice ng215 says coming off can take months, that medicines should not be stopped abruptly except in exceptional circumstances, and that tapers should get smaller as the dose gets lower [nice-2022]; the royal college of psychiatrists conceded in 2019 that for some people withdrawal is severe and long-lasting, while stating that antidepressant use is not dependence in the addiction sense [rcpsych-2019].
questions to ask your prescriber about escitalopram
each one comes from a warning or a study above. they are questions, not instructions; the answers depend on a history nobody here has.
- given my age, which side of the boxed warning’s line am i on, and what exactly should i or the people around me watch for in the first two months?
- the trials found 10 mg and 20 mg similar on the depression scale, and the side-effect rates roughly double at 20 mg. which dose am i on, and why?
- the label says to ask about sexual function before starting and during treatment. can we do that now, and how would we tell a drug effect from the depression itself?
- i take ibuprofen or naproxen for pain, or a blood thinner. does the bleeding warning change what i should use instead?
- the fda-submitted trials show a modest average benefit with a minority responding strongly. how will we tell early on which group i am in?
- if i ever want to stop, what would the taper look like, how small are the steps near the end, and how would we tell withdrawal from relapse?
- the over-65 trial result depended on how it was counted, and drowsiness was common. does my age change the dose or when i take it?
questions people ask
- does escitalopram have a black box warning?
- yes. the fda label carries one boxed warning, on suicidal thoughts and behaviors in children, adolescents and young adults in short-term studies, and it states that escitalopram is not approved under age 7. the label’s pooled numbers per 1,000 people treated are 14 additional cases under age 18, 5 additional at 18 to 24, 1 fewer at 25 to 64 and 6 fewer at 65 and over.
- what are the most common escitalopram side effects?
- from the label’s depression trials, 715 people on escitalopram against 592 on placebo: nausea 15% vs 7%, insomnia 9% vs 4%, diarrhea 8% vs 5%, sleepiness 6% vs 2%, dry mouth 6% vs 5%, sweating, fatigue and dizziness about 5% each. several roughly double between 10 mg and 20 mg: insomnia 7% to 14%, diarrhea 6% to 14%, sleepiness 4% to 9%.
- does escitalopram cause sexual side effects?
- the label has a dedicated warning (5.11) and a table: in men, ejaculation disorder 12% vs 1% on placebo, decreased libido 6% vs 2%, impotence 2% vs under 1%; in women, decreased libido 3% vs 1% and anorgasmia 3% vs under 1%. the label says these figures are likely to underestimate the true rate. when researchers asked with a questionnaire, escitalopram ranked near the bottom of ten antidepressants for sexual dysfunction. in 2019 the european regulator required a warning that sexual dysfunction can persist after stopping.
- what happens if you stop escitalopram suddenly?
- the label lists a discontinuation syndrome after abrupt stopping: low mood, irritability, agitation, dizziness, electric-shock sensations, anxiety, confusion, headache, insomnia and hypomania, usually self-limiting but with serious cases reported. it recommends gradual reduction and, if a step brings intolerable symptoms, that the prescriber consider returning to the previous dose and going slower. a taper plan is a conversation with a prescriber, not something to decide from a web page.
- is 10 mg or 20 mg of escitalopram better?
- the label’s fixed-dose trial found 10 mg and 20 mg a day similar on the depression rating scale, while the side-effect table shows insomnia, diarrhea, sleepiness and sweating roughly twice as common at 20 mg. the label’s recommended dose in liver impairment is 10 mg. which dose fits a given person is a prescriber’s call; the label gives the numbers to ask about.
sources for this section
the library rows link to our one-page summary of each study, with the original paper, its funding and our evidence grade on that page.
- escitalopram tablets prescribing information, fda label on dailymed (set id 9ddd1f24-3ebd-4307-bb23-6acd742cd140, version 1, effective july 24, 2026): boxed warning; sections 5.1 to 5.11, 6.1 tables 4 and 5, 14.1
- ahrq medical expenditure panel survey, prescribed medicines public-use file 2024 (hc-254a): people with at least one escitalopram purchase, weighted; computed by veisund, method on the usage section of this page
- the antidepressant suicidality warning has an age ceiling most people never hear about (fda boxed warning, read off the label) (library row)
- cipriani a, et al. comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. lancet 2018 (library row)
- cipriani a, et al. comparative efficacy and acceptability of 12 new-generation antidepressants. lancet 2009 (library row)
- cipriani a, et al. escitalopram versus other antidepressive agents for depression. cochrane database of systematic reviews 2009 (library row)
- stone mb, et al. response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the fda. bmj 2022 (library row)
- lenze ej, et al. escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. jama 2009 (library row)
- langley c, et al. chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity. neuropsychopharmacology 2023 (library row)
- serretti a, chiesa a. treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. journal of clinical psychopharmacology 2009 (library row)
- european medicines agency, pharmacovigilance risk assessment committee. recommendations on signals, 13 to 16 may 2019, section 1.3: ssris and snris, persistent sexual dysfunction after drug withdrawal (library row)
- anglin r, et al. risk of upper gastrointestinal bleeding with ssris with or without concurrent nsaid use: a systematic review and meta-analysis. american journal of gastroenterology 2014 (library row)
- national institute for health and care excellence. medicines associated with dependence or withdrawal symptoms (ng215), 2022 (library row)
- royal college of psychiatrists. position statement on antidepressants and depression (ps04/19), 2019 (library row)
How long the escitalopram trials actually ran
The longest trial behind the escitalopram approval ran 8 weeks.
The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.
People often stay on these drugs for far longer than the trials ran. The trials behind the approval ran 8 weeks.
That does not mean longer use is unsafe. It does not mean the drug stops working either. It means longer use was never the thing that got tested.
If you have been on it a long time, that is a fair thing to ask your prescriber about.
Boxed warning: suicidal thoughts and behaviors
The strongest warning the FDA puts on a label, often called a black box warning. It is reproduced below word for word, not summarised.
This is the strongest warning the FDA can put on a drug label. Some people call it a black box warning. We copied it word for word. We did not shorten it and we did not soften it.
The warning below is about suicidal thoughts. In short studies, antidepressants raised the risk of suicidal thoughts and behavior. That was in children and young adults. The label tells prescribers to watch every patient closely for this. It also tells them to watch for the illness getting worse.
The FDA’s own words follow, copied exactly.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning . Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Escitalopram tablets are not approved for use in pediatric patients less than 7 years of age ( 8.4 ). WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. Escitalopram tablets is not approved for use in pediatric patients less than 7 years of age [see Use in Specific Populations ( 8.4) ].
FDA label effective July 24, 2026 — read the full label on DailyMed
What escitalopram is FDA approved for, and the trials behind it
Approved for major depressive disorder in adults in 2002, under application NDA 021323. Source: FDA Drugs@FDA.
The label does not report per-study enrollment for the three acute trials; the participant figure here is the pooled count from the label's safety section.
Three 8-week placebo-controlled studies in outpatients aged 18 to 65 established efficacy for depression; two of them also included citalopram as an active comparator. In a longer-term trial, 274 patients who had responded to 8 weeks of open-label escitalopram were randomized to continued escitalopram or placebo for up to 36 weeks, with a longer time to relapse on escitalopram. A further 8-week placebo-controlled study supported the later indication in adolescents aged 12 to 17.
One gap first. The label does not say how many people were in each of the three short trials. The patient count here is the pooled figure from its safety section.
The FDA approved escitalopram in 2002. The approved use was major depression in adults. The file number is NDA 021323. The source is Drugs@FDA, the FDA's own database.
Three 8-week trials against a placebo backed the depression approval. Everyone was an outpatient aged 18 to 65. Two of them also had a citalopram arm to compare against.
In a longer trial, 274 people had done well over 8 open weeks. They were split by chance. Some stayed on the drug and some moved to a placebo, for up to 36 weeks. Those who stayed on it went longer before getting ill again.
One more 8-week trial against a placebo backed the later use in teens aged 12 to 17.
- Trials
- 3 placebo-controlled trials
- Duration
- 8 weeks
- Participants
- 715 patients on escitalopram in the placebo-controlled trials
- Compared against
- Placebo; citalopram as an active comparator in two studies
The efficacy of escitalopram as a treatment for major depressive disorder was established in three, 8-week, placebo-controlled studies conducted in outpatients between 18 and 65 years of age who met DSM-IV criteria for major depressive disorder.
Verbatim from the escitalopram FDA label, Clinical Studies section, effective July 24, 2026 — read the full label on DailyMed.
Side effects of escitalopram in the approval trials
Incidence among 715 patients on escitalopram versus 592 on placebo in double-blind, placebo-controlled depression trials in adults. The label cautions that trial rates cannot be directly compared with rates for other drugs and may not reflect the rates observed in practice.
Read the limits first. These numbers come from adult depression trials against a placebo. Nobody in them knew who got the drug. 715 people took it and 592 took a placebo.
The label warns that you cannot line these rates up against another drug’s rates. It warns that real life may not match them either.
- Nausea (15% vs 7% on placebo)
- Insomnia (9% vs 4%)
- Ejaculation disorder (9% vs under 1%, male patients)
- Diarrhea (8% vs 5%)
- Somnolence (6% vs 2%)
- Dry mouth (6% vs 5%)
- Increased sweating (5% vs 2%)
- Fatigue (5% vs 2%)
- Dizziness (5% vs 3%)
- Decreased appetite (3% vs 1%)
- Decreased libido (3% vs 1%)
The most commonly observed adverse reactions in escitalopram patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were insomnia, ejaculation disorder (primarily ejaculatory delay), nausea, sweating increased, fatigue, and somnolence.
From the escitalopram FDA label, Adverse Reactions section, effective July 24, 2026 — DailyMed.
More from the escitalopram label: drug abuse and dependence
Abuse and dependence not systematically studied
Escitalopram has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence; animal studies suggest the abuse liability of racemic citalopram is low. Premarketing experience showed no drug-seeking behavior, but the label advises evaluating patients for a history of drug abuse and watching for signs of misuse.
FDA label, Drug Abuse and Dependence section.
Discontinuation syndrome
The label reports adverse reactions on stopping, particularly when abrupt, including dysphoric mood, irritability, dizziness, sensory disturbances such as electric shock sensations, insomnia, and hypomania. While generally self-limiting, serious discontinuation symptoms have been reported; a gradual reduction in dose rather than abrupt cessation is recommended whenever possible.
FDA label, Warnings and Precautions section.
How many Americans take escitalopram
Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.
These are federal survey numbers. They come out about two years late. They count prescriptions filled. They do not tell you if the drug helped.
- 41,800,787
- prescriptions in the United States (2024), refills included
- 9,460,411
- people filling them (2024), ± 959,730 (95%)
Prescriptions are up 113% from 2014 to 2024, a change larger than the survey’s margin of error. Whatever you decide about escitalopram, you are deciding alongside about 9,460,411 other people in 2024.
Prescriptions by year: 2014 19,639,202 · 2015 24,068,904 · 2016 25,240,490 · 2017 25,960,468 · 2018 25,978,773 · 2019 27,510,959 · 2020 30,605,647 · 2021 30,505,719 · 2022 30,750,612 · 2023 37,088,585 · 2024 41,800,787.
Prescriptions are up 113 percent since 2014. About 9.5 million people in the United States took it in 2024.
Correction (29 September 2026). An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It showed 9,451,175 people and 41,773,078 prescriptions for 2024; the file gives 9,460,411 and 41,800,787.
Source: AHRQ Medical Expenditure Panel Survey (MEPS), Prescribed Medicines public-use files, 2014 (HC-168A) through 2024 (HC-254A), computed by veisund. People with at least one purchase where the Multum generic name (RXDRGNAM) equals the drug, weighted by the year’s person weight; purchases include refills. Standard errors by Taylor linearization on VARSTR/VARPSU. AHRQ’s reliability rule: a year is not shown when fewer than 60 survey respondents reported the drug or the relative standard error is over 50%. AHRQ cautions that its 2018 questionnaire redesign and the 2020–2022 pandemic years make year-to-year comparisons less certain.
What people report to the FDA about escitalopram
Read this before the numbers.
Anyone can file an adverse event report — patients, doctors, manufacturers — and nobody verifies that the drug caused what was reported. There is no denominator: tens of millions of prescriptions generate reports at an unknowable rate, and reporting rises with news coverage, not necessarily with harm. Counts below are report volumes, not rates, and cannot be compared between drugs. The FDA itself says not to use this data to make medical decisions — we show it because you deserve to see what is in the public record, with its limits stated plainly.
Read this before the numbers.
Anyone can send a report to the FDA. Patients can. Doctors can. Drug makers can. Nobody checks that the drug caused what the report describes.
There is also no bottom number. Tens of millions of prescriptions turn into reports at a rate nobody knows. Reports go up when a drug is in the news, and that is not the same as more harm.
So these are counts of reports. They are not rates. You cannot use them to compare one drug with another. The FDA itself says not to use this data to make medical choices.
We show it because it is on the public record, and you should get to see it with its limits named.
- 139,512
- reports mentioning escitalopram, all time
- 93,562
- filed as serious (a report-level flag covering every drug and outcome in the report)filed as serious. That flag covers the whole report, and one report can name more than one drug and more than one outcome.
Most-reported reactions
- Fatigue9,542
- Nausea9,514
- Drug ineffective8,998
- Headache7,397
- Diarrhoea7,045
- Anxiety6,668
- Dizziness6,313
- Off label use6,211
- Depression6,157
- Pain5,823
“Drug ineffective” ranking this high is worth noticing: a report of not being helped counts as an adverse event too, and people file them in large numbers.
It is worth noticing how high “drug ineffective” ranks. A report that the drug did not help counts as an adverse event too. People file a lot of them.
Source: FDA Adverse Event Reporting System (FAERS), via openFDA, openFDA dataset refreshed 2026-07-30 (the refresh date of the query endpoint, not the date reports run through).
Drug interactions listed on the escitalopram label
The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.
Below is the part of the FDA label that lists other drugs. It is copied word for word.
No list on the web can see what else you take. A pharmacist can. Ask one to check your full list.
Read the label’s interactions section
7 DRUG INTERACTIONS • Concomitant use with SSRIs, SNRIs or Tryptophan is not recommended ( 7 ) • Use caution when concomitant use with drugs that affect Hemostasis (NSAIDs, Aspirin, Warfarin) ( 7 ) Table 6 presents clinically important drug interactions with escitalopram. TABLE 6 Clinically Important Drug Interactions with Escitalopram Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs, including Escitalopram, and MAOIs increases the risk of serotonin syndrome. Intervention: Escitalopram is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Dosage and Administration ( 2.7 ), Contraindications ( 4 ), and Warnings and Precautions ( 5.2 )] . Pimozide Clinical Impact: Concomitant use of racemic citalopram with pimozide increases plasma concentrations of pimozide, a drug with a narrow therapeutic index, and may increase the risk of QT prolongation and/or ventricular arrhythmias compared to use of racemic citalopram alone [see Clinical Pharmacology ( 12.3 )] . Intervention: Escitalopram is contraindicated in patients taking pimozide [see Contraindications ( 4 )] . Other Serotonergic Drugs Clinical Impact: Concomitant use of Escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort) increases the risk of serotonin syndrome. Intervention: Monitor patients for signs and symptoms of serotonin syndrome, particularly during Escitalopram initiation and dosage increases. If serotonin syndrome occurs, consider discontinuation of Escitalopram and/or concomitant serotonergic drugs [see Warning and Precautions ( 5.2 )] . Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.) Clinical Impact: Concomitant use of Escitalopram and an antiplatelet or anticoagulant may potentiate the risk of bleeding. Intervention: Inform patients of the increased risk of bleeding associated with the concomitant use of Escitalopram and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio [see Warning and Precautions ( 5.7 )] . Sumatriptan Clinical Impact: There have been postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of an SSRI and sumatriptan. Intervention: If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised [see Warning and Precautions ( 5.2 )] . Carbamazepine Clinical Impact: Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Intervention: Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered. Drugs Metabolized by CYP2D6 Clinical Impact: Coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. Intervention: The clinical significance of this finding is unknown. Exercise caution during coadministration of escitalopram and drugs metabolized by CYP2D6.
FDA label for escitalopram, effective July 24, 2026 — DailyMed.
Label history: when this label changes, it is recorded in What changed.
Who pays for escitalopram
Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.
- Medicare Part D
- Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 2,728,707 beneficiaries filled 12,700,559 claims in 2024 — 2,346,027 aged 65 and over, and 382,680 under 65.
- Medicaid
- At least 6,618,277 prescriptions in 2024 — a floor, because 98 of 705 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.
- All payers (survey estimate)
- A survey estimate from 553 respondents, which we computed from AHRQ’s MEPS 2024 Prescribed Medicines file (people with at least one purchase, weighted; purchases include refills), puts the whole country at 41,800,787 purchases and 9,460,411 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.
- The population nobody counts
- The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of escitalopram specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.
Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.
Who has been paying for escitalopram, 2019–2024
Medicare Part D
Claims, all ages — the one payer with a public per-drug series.
9,881,846 → 12,700,559 claims
Medicare under 65
Beneficiaries, not ordinary working-age adults: Medicare before 65 means the disabled and dual-eligible population. A gap is a suppressed split, not zero.
384,976 → 382,680 beneficiaries
Medicaid
A floor each year — small-cell rows are suppressed federally and excluded from the sum.
5,100,869 → 6,618,277 prescriptions (floor)
Commercially insured adults
No public dataset publishes per-drug commercial claims for any year — the absence is the finding, and it is rendered, not interpolated. The population this library most wants to inform is the one with no public per-drug series, in any year — insurers and PBMs hold that data privately. What the federal surveys do measure — how many adults take these medications at all — is on the adult-usage page.
Sources: Medicare Part D Prescribers by Geography and Drug (data.cms.gov, national rows, per data year); Medicaid State Drug Utilization Data (data.medicaid.gov, national rows). Claims, fills and beneficiaries are different units — compare each series only with itself.
The escitalopram approval, step by step
Step 1
What the approval was actually based on
Which studies did the FDA rely on, how long did they run, and who was in them?
The efficacy of Lexapro as a treatment for major depressive disorder was established in three, 8-week, placebo-controlled studies conducted in outpatients between 18 and 65 years of age who met DSM-IV criteria for major depressive disorder.
FDA-approved labelling, 14 CLINICAL STUDIES 14.1 Major Depressive Disorder — read the label on DailyMed
Our reading
Three trials, eight weeks each, in outpatients aged 18 to 65 who were screened to fit a single diagnosis. If you are over 65, if you have more than one thing going on, or if you have been taking it for longer than two months, you are outside the population that was studied for approval.
Step 2
The approval
When was it approved, under what application, and by whose review?
- Approved
- August 14, 2002
- Application
- NDA021323
- Review
- STANDARD
- Original sponsor
- Forest Laboratories (now AbbVie)
- Holds it now
- AbbVie
- Label submissions since
- 30
Source: openFDA Drugs@FDA, original application ORIG-1
Step 3
What was added after it was on the market
Which warnings arrived only after millions of people were already taking it?
PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC meeting, section 1.3: SNRIs and SSRIs - persistent…
17 years after approval
On 16 May 2019 the EU drug regulator's safety committee ordered every manufacturer of citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, and milnacipran to add this warning within two months: "There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI." The patient leaflet wording is "In some cases, these symptoms have continued after stopping treatment." This is a regulator acting on case reports and pharmacovigilance data, not a prevalence study — how often it happens is still unknown, and that uncertainty cuts both ways.
Worth asking
European regulators require a label warning that sexual side effects can persist after stopping an SSRI or SNRI — how would you and I tell that apart from the depression itself if it happened to me?
The antidepressant suicidality warning has an age ceiling most people never hear about
Antidepressants carry a boxed warning about suicidal thoughts and behaviour in children, adolescents and young adults. It came from pooling 24 short-term placebo-controlled trials of nine antidepressants in more than 4,400 young patients: suicidality was reported in about 4% on drug against 2% on placebo. There were no completed suicides in those trials.
The part that usually gets lost is the age boundary, which is in the label itself. The studies did not show an increased risk above age 24, and in patients 65 and older the risk went in the other direction — it was reduced. The warning is real and it is specific, not a blanket statement about everyone who takes one.
Worth asking
Given my age, which side of that line am I on, what specifically should I or the people around me watch for in the first two months, and who do I call if it happens.
Step 4
What independent research has found since
What has been learned by people who were not selling it?
Cochrane 2021: newer antidepressants cut depression in children and teens by a small and unimportant amount
19 years after approval
The Cochrane review of newer antidepressants for depression in children and teenagers, and the one that disagreed with the Lancet reviews on fluoxetine.
Significant findings
Hetrick and colleagues pooled 26 randomised trials of newer antidepressants in 6 to 18 year olds with major depression, searched to March 2020. Older drugs (tricyclics and MAO inhibitors) were not included. On the clinician-rated CDRS-R scale (17 to 113 points), most drugs gave a "small and unimportant" drop in symptoms compared with placebo. Fluoxetine: 2.84 points (95% CI 1.56 to 4.12), moderate certainty. Sertraline (3.51), escitalopram (2.62), duloxetine (2.70) and paroxetine (1.43) were in the same range. Differences between most of the drugs were also "small and unimportant".
No trial reported the two primary outcomes, diagnosis by clinical interview and suicide. Suicide-related outcomes were uncommon and the estimates wide. For fluoxetine the odds ratio was 1.27 (0.87 to 1.86): low certainty that it may at least slightly raise those odds. Most trials excluded young people at risk of suicide, so the review cannot speak for them.
The other direction
The review does not say these drugs are useless. Averages hide people who respond more. The authors say sertraline, escitalopram, duloxetine and fluoxetine "could be considered as a first option", with close monitoring of treatment effects and suicide-related outcomes, and that therapy, particularly CBT, remains important. They also say methodological shortcomings in the trials make the findings hard to interpret.
Why it matters now
Because it left out tricyclics, this review did not include a small 2006 trial of fluoxetine against nortriptyline. A 2026 re-analysis (Lyus and colleagues, in this library) found that trial is what made fluoxetine look larger in the two Lancet reviews, including Cipriani 2016 (also in this library). Without it, all three land close to this review's estimate.
What this does not show
It does not tell any family whether to start, keep or stop a medicine. If your child takes fluoxetine, this is a question for their prescriber, not a reason to stop.
Worth asking
What size of change should we expect, how will we measure it, and how will suicide-related thinking be watched?
In 66 healthy volunteers, three weeks of escitalopram dulled the response to reward and punishment
21 years after approval
The experiment that separates the drug from the depression, by giving the drug to people who do not have the depression.
Significant findings
Langley, Armand, Luo and colleagues at the University of Copenhagen ran a double-blind placebo-controlled study in 66 healthy volunteers, semi-randomised to 20 mg of escitalopram (32 people) or placebo (34), balanced for age, sex and IQ, for at least 21 days. They measured "cold" cognition (inhibition, cognitive flexibility, memory) and "hot" cognition (decision-making and especially reinforcement learning), with questionnaires and serum escitalopram levels alongside.
"The novel and important finding was that escitalopram reduced reinforcement sensitivity compared to placebo on both the Sequential Model-Based/Model-Free task and the PRL task." Reinforcement sensitivity is how much a person's choices shift in response to reward and punishment. "We found no other significant group differences on 'cold' or 'hot' cognition."
The link the authors draw: "Lower reinforcement sensitivity in response to chronic SSRI administration may reflect the 'blunting' effect often reported by patients with MDD treated with SSRIs." The study is registered as NCT04239339.
The other direction
Sixty-six people, one drug, one dose, three weeks. The measure is a task score in a lab, not a feeling; the abstract does not report that the escitalopram group felt flatter, only that their learning responded less to reward and punishment. The authors write "may reflect," not "is." Semi-randomised means allocation was balanced by hand on age, sex and IQ rather than fully random. And nothing else changed: memory, inhibition and flexibility were intact, which is a finding in the drug's favour as much as against it.
What this does not show
It does not say how the effect behaves over months, or whether it fades after stopping. It was done in people without depression, so it cannot say how the same effect plays out in someone whose illness already dulls reward. It is not a reason to change a prescription.
Worth asking
If part of my flatness is the drug, what are the options, and what does each one risk for the mood it is holding?
Two weeks of escitalopram left psilocybin's positive effects intact and reduced its bad ones, in a crossover trial
20 years after approval
The controlled experiment on the antidepressant plus psilocybin question, run by the same Basel group that studied MDMA and citalopram twenty years earlier.
Significant findings
Becker and colleagues (Clinical Pharmacology and Therapeutics, 2022) used "a double-blind, placebo-controlled, crossover design with two experimental test sessions to investigate the response to psilocybin (25 mg) in healthy subjects after pretreatment with escitalopram or placebo." Pretreatment was escitalopram 10 mg daily for 7 days then 20 mg for 7 days, including the psilocybin day, against 14 days of placebo.
"Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects of psilocybin compared with placebo pretreatment. Escitalopram did not alter the pharmacokinetics of psilocin." Nor did it change QTc intervals, BDNF levels or the expression of the serotonin receptor and transporter genes measured.
The authors' own limit: "Further studies are needed with a longer antidepressant pretreatment time and patients with psychiatric disorders to further define interactions between antidepressants and psilocybin."
Worth asking
Fourteen days of escitalopram in healthy people is not years of sertraline in someone with depression, and the survey row beside this one found half of such people report weaker effects. Read together: an SSRI does not appear to make psilocybin dangerous, may soften its worst moments, and may blunt it for some people, especially with longer use. What the trial does not test is the thing people actually do, which is take mushrooms of unknown dose outside a clinic. Funding note: this study was supported in part by Mind Medicine, a psychedelic drug developer, and the senior author consults for it.
SSRIs raise the odds of a stomach bleed by about two thirds; with an NSAID as well, about fourfold
12 years after approval
Serotonin is needed for platelets to clump. Antidepressants that block its reuptake reduce the platelet store, and this meta-analysis measured what that does to the risk of bleeding from the stomach, alone and with an anti-inflammatory painkiller.
Significant findings
Anglin and colleagues (American Journal of Gastroenterology, 2014) searched to April 2013 and included "Fifteen case-control studies (including 393,268 participants) and four cohort studies". "There was an increased risk of upper GI bleeding with SSRI medications in the case-control studies (OR=1.66, 95% CI=1.44,1.92) and cohort studies (OR=1.68, 95% CI=1.13,2.50)."
The absolute numbers: "The number needed to harm for upper GI bleeding with SSRI treatment in a low-risk population was 3,177, and in a high-risk population it was 881." And the combination: "The risk of upper GI bleeding was further increased with the use of both SSRI and NSAID medications (OR=4.25, 95% CI=2.82,6.42)."
The authors' conclusion: "SSRI medications are associated with a modest increase in the risk of upper GI bleeding, which is lower than has previously been estimated. This risk is significantly elevated when SSRI medications are used in combination with NSAIDs, and physicians prescribing these medications together should exercise caution and discuss this risk with patients."
Worth asking
The number needed to harm is the one to hold on to: on an SSRI alone, one extra bleed for roughly every three thousand low-risk people, or every nine hundred high-risk. The combination with regular NSAID use is where the risk stops being modest. If you take an SSRI and buy ibuprofen or naproxen for pain, the question for the pharmacist is what the alternative is, and whether you count as high risk (prior ulcer, older age, anticoagulants, steroids).
Half of people on an SSRI or SNRI reported weaker mushroom effects, lasting up to three months after stopping
21 years after approval
People taking mushrooms while on an antidepressant report a specific thing: it does less. This survey measured how often, and for how long after stopping.
Significant findings
Gukasyan and colleagues (Journal of Psychopharmacology, 2023) ran an online retrospective survey of people who had used psilocybin mushrooms with an antidepressant or within two years of stopping one, comparing the strength of effects with the same dose before the antidepressant or with companions not on one.
"In reports (n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41-0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44-0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2-0.39] (bupropion)."
After stopping: "Following SSRI/SNRI discontinuation (n = 1,542 reports), the probability of reduced drug effects was not significantly different from the earliest post-discontinuation timepoint (within 1 week) until 3-6 months, probability = 0.3 [0.20-0.46], p = 0.001." Removing fluoxetine, which lingers in the body, did not change that. "SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant. This dampening effect may last as long as 3 months following antidepressant discontinuation."
Worth asking
A survey of people who chose to answer cannot give a true rate, and "weaker than expected" is a memory. What it does show is the shape: serotonergic antidepressants blunt psilocybin, bupropion much less, and the blunting outlasts the drug by weeks to months. The Becker 2022 row beside this one is the controlled trial, which found the good effects intact and the bad ones reduced after two weeks of escitalopram. The two are not in conflict; they measured different things over different durations. What neither supports is stopping an antidepressant to make mushrooms work, which trades a known risk for an unmeasured one.
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major…
16 years after approval
Across 522 randomised trials with 116,477 adults, escitalopram stood out as one of the few antidepressants that was both more effective and better tolerated than most others in direct head-to-head comparisons.
Worth asking
Escitalopram ranked near the top for both effectiveness and tolerability in the largest antidepressant comparison to date - is that why it was picked for me?
Escitalopram versus other antidepressive agents for depression
7 years after approval
Pooling 22 randomised trials (about 4,000 people), escitalopram was modestly more effective than citalopram and fluoxetine, and fewer people stopped it than stopped duloxetine.
Worth asking
Escitalopram edged out its parent drug citalopram in head-to-head trials - is there a cost or coverage reason to choose one over the other in my case?
Escitalopram versus other antidepressive agents for depression — Cipriani A, et al. (2009)
Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the…
20 years after approval
Analysing individual data from 73,388 people in 232 placebo-controlled trials submitted to the FDA (including escitalopram's), antidepressants beat placebo by an average of 1.75 points on a 52-point depression scale, with roughly 15% of patients getting a substantial benefit beyond the placebo response.
Worth asking
On average the drug-versus-placebo difference is modest but a minority of people respond strongly - how will we tell early on which group I am in?
Withdrawal from these medications can take months, and NICE says so
20 years after approval
NICE guideline NG215 covers safe prescribing and managed withdrawal for five groups of medication: opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. It is the closest thing there is to an official answer on how coming off actually goes.
It states that withdrawal can be difficult and may take several months or more, that symptoms vary widely in type and severity, that they affect both physical and mental health, and that they can be delayed in onset and can persist. Two recommendations are worth quoting to a prescriber. Do not stop a medicine abruptly except in exceptional medical circumstances. And taper using a slow, stepwise reduction proportionate to the current dose, so the decrements get smaller as the dose gets lower — not a fixed cut each time.
That last detail is the one most commonly missed. Gabapentinoids are the exception in the guideline and are reduced by a fixed amount at each step.
Worth asking
Can we write the taper down, what size are the steps near the end, and how long do I hold at each step before the next reduction.
In 2019 the Royal College of Psychiatrists changed its position on withdrawal
17 years after approval
For years people reporting long, severe antidepressant withdrawal were told it lasted a week or two. In May 2019 the Royal College of Psychiatrists published a position statement conceding the point: while withdrawal symptoms are often mild and self-limiting, there is substantial variation, and for some patients symptoms last much longer and are more severe.
It went further and asked for changes — that guidelines and patient information recognise the potential for severe and long-lasting withdrawal, that pharmacologically-informed tapering guidance be developed, that discontinuation be tapered at a rate the patient can tolerate over potentially several months, and that clinicians actively work to tell withdrawal apart from relapse.
One thing it explicitly does not say, and it is worth being accurate about: the College states that from a clinical perspective antidepressant use is not associated with dependence in the addiction sense. Withdrawal and dependence are not the same claim.
Worth asking
If I feel bad three weeks after a dose reduction, how will we decide whether that is withdrawal or my depression returning, and what do we do differently in each case.
Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial
7 years after approval
In 177 adults aged 60 and over with generalized anxiety disorder, 69% responded to escitalopram within 12 weeks versus 51% on placebo (P = .03). That is the completer analysis. The trial's intention-to-treat analysis, which counts everyone who started rather than only those who finished, found no statistically significant difference: 57% versus 45% (P = .11). Fatigue and sleepiness were the most common side effect, at about 41%.
Which number you believe depends on how much weight you give to the people who left the trial. Intention-to-treat is the more conservative reading, and it did not clear the significance threshold.
Worth asking
The benefit here depended on how the trial was analysed, and drowsiness was common - does my age change the dose or the timing of when I take escitalopram?
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
7 years after approval
Across 117 randomised trials with 25,928 adults, escitalopram was among the four most effective of 12 newer antidepressants and, with sertraline, had the best acceptability profile (fewest people stopping treatment).
Worth asking
Escitalopram was one of the least-discontinued antidepressants in this analysis - what side effects, if any, most often make your patients stop it?
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.
7 years after approval
When sexual function is actually asked about with a questionnaire rather than waited for as a spontaneous complaint, treatment-emergent sexual dysfunction ranged from 25.8% to 80.3% of patients across antidepressants, all significantly above placebo. In descending order of impact the drugs were sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram, and fluvoxamine. Agomelatine, amineptine, bupropion, moclobemide, mirtazapine, and nefazodone showed no significant difference from placebo.
Worth asking
Where does the antidepressant I'm on sit on the sexual side-effect ranking, and is there a drug with a lower rate that would still treat my condition?
Step 5
What still is not known
Which questions you might reasonably have has nobody answered yet?
- Does it still outperform placebo at year two, year five, year ten? The approval did not ask.
- What does coming off after long-term use look like? Withdrawal was not a registration endpoint.
- How does it perform in the over-65s, who were excluded from the pivotal trials but are prescribed it routinely?
The escitalopram legal and safety record
Settled and adjudicated matters only, from primary sources — including the litigation that was decided for the manufacturer, and the cases this drug is verifiably not part of.
Deciding about escitalopram?
- Side-effect rates from escitalopram's own label — drug vs placebo, with every caveat the label attaches
- How long every medication's approval trials ran — escitalopram beside every other drug in the library, from the same FDA record
- 12 questions to ask before starting a psychiatric medication — each with the study behind it
- Already on it? The 10-question annual review — including the honest case for staying
- How long every drug here was tested before approval — one chart, all medications
Open escitalopram (Lexapro) in veisund
The app has the full approval journey, the resources behind it, and people working through the same questions.
